Trial reportNature medicine2014
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.
Trial report in Nature medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
178 citing papers in PubMed, 3 syntheses or guidelines pooled it, 383 citations in OpenAlex.
- The predictive value of machine learning for the response to anti-TNF-α therapy in patients with Crohn's disease: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Pooled it
- Confocal Laser Endomicroscopy in Gastrointestinal and Pancreatobiliary Diseases: A Systematic Review and Meta-Analysis.BioMed research international · 2016Pooled it
- Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease.Inflammatory bowel diseases · 2021Trial
- Uninflamed colonic tissue harbors humoral activity linked to anti-TNF therapy non-response in ulcerative colitis.iScience · 2026Article
- Multiple Modes of Action of Anti-TNF-α Antibodies for Inflammatory Bowel Diseases Beyond TNF-α Neutralization.Antibodies (Basel, Switzerland) · 2026Review
- Artifact-suppressed dual-modality OCT-fluorescence endoscopic imaging of colitis in murine models.Biomedical optics express · 2026Article
- Adipocyte-Derived Leptolin Enhances Energy Expenditure and Prevents Obesity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Higher Colonic Tissue Drug Concentrations of Subcutaneous Compared to Intravenous Administration of Infliximab Therapy in Patients With Inflammatory Bowel Disease.United European gastroenterology journal · 2026Observational
- New Technologies for IBD Endoscopy.Journal of clinical medicine · 2026Review
- Optimizing Drug Positioning in IBD: Clinical Predictors, Biomarkers, and Practical Approaches to Personalized Therapy.Biomedicines · 2026Review
- An in vivo Insect-based Platform for Preclinical Endoscopic Imaging.Endoscopy international open · 2026Article
- Spatial multi-omics-guided drug development in inflammatory bowel disease: from mucosal immune niches to precision therapy.Frontiers in immunology · 2026Review
- Real-time microscopic visualisation: current applications and challenges of confocal laser endomicroscopy in the diagnosis and treatment of small bowel disorders.Therapeutic advances in gastroenterology · 2026Review
- Predicting mucosal healing in Crohn's disease: development of a deep-learning model based on intestinal ultrasound images.Insights into imaging · 2025Article
- Transforming Gastrointestinal Diagnosis with Molecular Endoscopy: Challenges and Opportunities.International journal of molecular sciences · 2025Review
- Confocal Endomicroscopy Intestinal Epithelial Barrier Abnormalities in Individuals Without Documented Gastro-Intestinal Disease.United European gastroenterology journal · 2025Article
- Artificial Intelligence in Inflammatory Bowel Disease Endoscopy.Diagnostics (Basel, Switzerland) · 2025Review
- Establishment and internal validation of a model to predict the efficacy of Adalimumab in Crohn's disease.Scientific reports · 2025Article
118 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
22 authors at 4 institutions in 2 countries.
Funding
Abstract
As antibodies to tumor necrosis factor (TNF) suppress immune responses in Crohn's disease by binding to membrane-bound TNF (mTNF), we created a fluorescent antibody for molecular mTNF imaging in this disease. Topical antibody administration in 25 patients with Crohn's disease led to detection of intestinal mTNF(+) immune cells during confocal laser endomicroscopy. Patients with high numbers of mTNF(+) cells showed significantly higher short-term response rates (92%) at week 12 upon subsequent anti-TNF therapy as compared to patients with low amounts of mTNF(+) cells (15%). This clinical response in the former patients was sustained over a follow-up period of 1 year and was associated with mucosal healing observed in follow-up endoscopy. These data indicate that molecular imaging with fluorescent antibodies has the potential to predict therapeutic responses to biological treatment and can be used for personalized medicine in Crohn's disease and autoimmune or inflammatory disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.